$6.92
2.12% today
Nasdaq, Feb 05, 04:23 pm CET
ISIN
CA29286M1059
Symbol
ENGN
Sector
Industry

EnGene Stock price

$6.78
-0.71 9.48% 1M
-1.27 15.78% 6M
+0.13 1.95% YTD
-1.21 15.14% 1Y
-3.08 31.24% 3Y
-3.08 31.24% 5Y
-3.08 31.24% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.09 1.35%
ISIN
CA29286M1059
Symbol
ENGN
Sector
Industry

Key metrics

Market capitalization $345.62m
Enterprise Value $132.24m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 1.27
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-62.30m
Cash position $238.40m
EPS (TTM) EPS $-1.50
P/E forward negative
Short interest 2.00%
Show more

Is EnGene a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

EnGene Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a EnGene forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a EnGene forecast:

Buy
100%

Financial data from EnGene

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Oct '24
+/-
%
- -
-
100%
- Direct Costs 0.32 0.32
78% 78%
-
-0.32 -0.32
78% 78%
-
- Selling and Administrative Expenses 23 23
29% 29%
-
- Research and Development Expense 38 38
-
-
-62 -62
88% 88%
-
- Depreciation and Amortization 0.32 0.32
78% 78%
-
EBIT (Operating Income) EBIT -62 -62
88% 88%
-
Net Profit -55 -55
46% 46%
-

In millions USD.

Don't miss a Thing! We will send you all news about EnGene directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

EnGene Stock News

Neutral
Business Wire
5 days ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder...
Neutral
Business Wire
6 days ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladde...
Neutral
Business Wire
about one month ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder...
More EnGene News

Company Profile

enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.

Head office Canada
CEO Ronald Cooper
Employees 57
Founded 2023
Website www.engene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today